Zomedica Stock Analysis

ZOM -  USA Stock  

USD 0.89  0.01  1.11%

The big decline in price over the last few months for Zomedica Pharmaceuticalsmay raise some interest from stakeholders as it is trading at a share price of 0.89 on 13,356,288 in trading volume. The company management teams failed to add value to investors and positioning the company supply of money to exploit market volatility in May. However, diversifying your holdings with Zomedica Pharmaceuticals or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.69. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Zomedica Pharmaceuticals Corp partners.
Check out Your Current Watchlist.

Search Stock Analysis 

 
Refresh
The Zomedica Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Zomedica Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Zomedica stock analysis module also helps to analyze the Zomedica Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Zomedica Stock Analysis Notes

The company recorded a loss per share of 0.05. Zomedica Pharmaceuticals had not issued any dividends in recent years. Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. Zomedica Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 19 people. For more information please call Robert Cohen at 734 369 2555 or visit http://zomedica.com.

Zomedica Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Zomedica Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Zomedica Pharmaceuticals Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Zomedica Pharmaceuticals generates negative expected return over the last 90 days
Zomedica Pharmaceuticals has high historical volatility and very poor performance
Zomedica Pharmaceuticals has some characteristics of a very speculative penny stock
Zomedica Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Reported Net Loss for the year was (16.91 M).
Zomedica Pharmaceuticals Corp has about 61.99 M in cash with (16.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06.
Latest headline from manometcurrent.com: Exercise or conversion by Robert Cohen of 1193750 shares of Zomedica Pharmaceuticals subject to Rule 16b-3

Zomedica Market Capitalization

The company currently falls under 'Small-Cap' category with total capitalization of 899.12 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Zomedica Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Zomedica Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has Return on Asset of (29.8) % which means that on every $100 spent on asset, it lost $29.8. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (51.94) %, meaning that it generated no profit with money invested by stockholders. Zomedica Pharmaceuticals management efficiency ratios could be used to measure how well zomedica pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 17th of June 2021, Zomedica Pharmaceuticals maintains the market risk adjusted performance of 0.9515, and Mean Deviation of 6.22. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zomedica Pharmaceuticals Corp, as well as the relationship between them. Specifically, you can use this information to find out if the company will indeed mirror its model of past data patterns, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Zomedica Pharmaceuticals, which can be compared to its rivals. Please check out Zomedica Pharmaceuticals variance and potential upside to decide if Zomedica Pharmaceuticals is priced fairly, providing market reflects its latest price of 0.89 per share. Given that Zomedica Pharmaceuticals Corp is a hitting penny stock territory we urge to closely look at its total risk alpha.

Zomedica Pharmaceuticals Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Zomedica Pharmaceuticals more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Zomedica Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zomedica Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zomedica Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zomedica Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Johnny Powers over a month ago via Macroaxis 
Exercise or conversion by Johnny Powers of 125000 shares of Zomedica Pharmaceuticals subject to Rule 16b-3
Christopher Wolfenberg over a month ago via Macroaxis 
Acquisition by Christopher Wolfenberg of 800000 shares of Zomedica Pharmaceuticals subject to Rule 16b-3
Ann Cotter over a month ago via Macroaxis 
Exercise or conversion by Ann Cotter of 8333 shares of Zomedica Pharmaceuticals subject to Rule 16b-3
Ann Cotter over two months ago via Macroaxis 
Exercise or conversion by Ann Cotter of 25000 shares of Zomedica Pharmaceuticals subject to Rule 16b-3
Johnny Powers over two months ago via Macroaxis 
Exercise or conversion by Johnny Powers of 100000 shares of Zomedica Pharmaceuticals subject to Rule 16b-3
Bruk Herbst over three months ago via Macroaxis 
Acquisition by Bruk Herbst of 3000000 shares of Zomedica Pharmaceuticals subject to Rule 16b-3
Ann Cotter over six months ago via Macroaxis 
Acquisition by Ann Cotter of 300000 shares of Zomedica Pharmaceuticals subject to Rule 16b-3
Ann Cotter over six months ago via Macroaxis 
Zomedica Pharmaceuticals exotic insider transaction detected
Christopher MacLeod over six months ago via Macroaxis 
Acquisition by Christopher MacLeod of 175000 shares of Zomedica Pharmaceuticals subject to Rule 16b-3
Johnny Powers over six months ago via Macroaxis 
Purchase by Johnny Powers of 625000 shares of Zomedica Pharmaceuticals
Robert Cohen over six months ago via Macroaxis 
Acquisition by Robert Cohen of 2000000 shares of Zomedica Pharmaceuticals subject to Rule 16b-3
Rodney Williams over a year ago via Macroaxis 
Acquisition by Rodney Williams of 200000 shares of Zomedica Pharmaceuticals subject to Rule 16b-3

Zomedica Pharmaceuticals Predictive Daily Indicators

Zomedica Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Zomedica Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Zomedica Pharmaceuticals Forecast Models

Zomedica Pharmaceuticals time-series forecasting models is one of many Zomedica Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zomedica Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Zomedica Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Zomedica Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Zomedica shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Zomedica Pharmaceuticals. By using and applying Zomedica Stock analysis, traders can create a robust methodology for identifying Zomedica entry and exit points for their positions.
Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. Zomedica Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 19 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Zomedica Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Idea Optimizer Now

   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module
Check out Your Current Watchlist. Note that the Zomedica Pharmaceuticals information on this page should be used as a complementary analysis to other Zomedica Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Zomedica Pharmaceuticals Stock analysis

When running Zomedica Pharmaceuticals stock analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' stock examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals stock's value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' stock value and its price as these two are different measures arrived at by different means. Investors typically determine Zomedica Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.